University of Pittsburgh Cancer Institute (UPCI)

New Therapeutic Target and Delivery

Laboratory research LCP members are defining molecular pathways that contribute to the development and progression of lung and thoracic malignancies. This basic research goal is defining molecular pathways that contribute to the development and progression of lung and thoracic malignancies. Related to this basic goal are three translational research goals: to improve therapy for thoracic cancers, to identify individuals at high risk for thoracic cancers, and to improve early detection of thoracic cancers.

Selected Publications

  • Vitamin D has been shown to have anti-proliferative effects in a wide variety of cancers including lung cancer. The anticancer effects of vitamin D are mediated primarily by its active metabolite, calcitriol, through vitamin D receptor (VDR) signaling. Immunohistochemical analysis shows that the nuclear but not the cytoplasmic VDR status may be a prognostic marker in lung cancer (Srinivasan M, et. al., J Steroid Biochem Mol Biol. 123:30-6, 2011).
  • Steroid hormones and growth factors affect lung cancer, and it is possible they act in concert to influence patient outcome. Recent results of LCP investigators show that hormonal and EGFR pathways together may contribute to lung cancer prognosis. Lung tumors with high estrogen receptor ERß -1 and low progesterone receptor may define patients with aggressive biology (Stabile LP, et. al., Clin Cancer Res. 17:154-64, 2011).

Members

Bigbee, William, PhD
Pathology
Pennathur, Arjun, MD
Surgery
Christie, Neil, MD
Surgery
Reilly, John, MD
Medicine
Dacic, Sanja, MD, PhD
Pathology
Socinski, Mark, MD
Medicine
Fuhrman, Carl, MD
Radiology
Stabile, Laura, PhD
Pharmacology & Chemical Biology
Greenberger, Joel, MD
Radiation Oncology
Weissfeld, Joel, MD, MPH
Epidemiology
Heron, Dwight, MD, FACRO
Radiation Oncology
Yousem, Samuel, MD
Pathology
Luketich, James, MD
Surgery